Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial.

Authors:
Address: Nutrition and Dietetic Research Group, Faculty of Medicine, Imperial College, London W12 0HS. mhickson@hhnt.nhs.uk
Journal:

Publication:
Free Text: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial.

abstract

OBJECTIVE:

To determine the efficacy of a probiotic drink containing Lactobacillus for the prevention of any diarrhoea associated with antibiotic Use and that caused by Clostridium difficile.

DESIGN:

randomised double blind placebo controlled study.

PARTICIPANTS:

135 hospital patients (mean age 74) taking antibiotics. Exclusions included diarrhoea on admission, bowel pathology that could result in diarrhoea, antibiotic use in the previous four weeks, severe illness, immunosuppression, bowel surgery, artificial heart valves, and history of rheumatic heart disease or infective endocarditis.

INTERVENTION:

Consumption of a 100 g (97 ml) drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus twice a day during a course of antibiotics and for one week after the course finished. The placebo group received a longlife sterile milkshake.

MAIN OUTCOME MEASURES:

Primary outcome: occurrence of antibiotic associated diarrhoea. Secondary outcome: presence of C difficile toxin and diarrhoea.

RESULTS:

7/57 (12%) of the probiotic group developed diarrhoea associated with antibiotic use compared with 19/56 (34%) in the placebo group (P=0.007). Logistic regression to control for other factors gave an odds ratio 0.25 (95% confidence interval 0.07 to 0.85) for use of the probiotic, with low albumin and sodium also increasing the risk of diarrhoea. The absolute risk reduction was 21.6% (6.6% to 36.6%), and the number needed to treat was 5 (3 to 15). No one in the probiotic group and 9/53 (17%) in the placebo group had diarrhoea caused by C difficile (P=0.001). The absolute risk reduction was 17% (7% to 27%), and the number needed to treat was 6 (4 to 14).

CONCLUSION:

Consumption of a probiotic drink containing L casei, L bulgaricus, and S thermophilus can reduce the incidence of antibiotic associated diarrhoea and C difficile associated diarrhoea. This has the potential to decrease morbidity, healthcare costs, and mortality if used routinely in patients aged over 50.

trial REGISTRATION:

National Research Register N0016106821.

Related Articles
Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.
Int Microbiol. 2004
Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.
Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Int Microbiol. 2004 Mar; 7(1):59-62.
Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children.
Aliment Pharmacol Ther. 2008
Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children.
Ruszczyński M, Radzikowski A, Szajewska H. Aliment Pharmacol Ther. 2008 Jul; 28(1):154-61. Epub 2008 Apr 13.
Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients.
Am J Gastroenterol. 2010
Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients.
Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Am J Gastroenterol. 2010 Jul; 105(7):1636-41. Epub 2010 Feb 9.
Review Treatment and prevention of antibiotic associated diarrhea.
Int J Antimicrob Agents. 2000
Review Treatment and prevention of antibiotic associated diarrhea.
Bergogne-Bérézin E. Int J Antimicrob Agents. 2000 Dec; 16(4):521-6.
Review The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea.
Nutr Clin Pract. 2009
Review The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea.
Rohde CL, Bartolini V, Jones N. Nutr Clin Pract. 2009 Feb-Mar; 24(1):33-40.
Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine.
BMC Microbiol. 2012
Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine.
Rehman A, Heinsen FA, Koenen ME, Venema K, Knecht H, Hellmig S, Schreiber S, Ott SJ. BMC Microbiol. 2012 Mar 27; 12:47. Epub 2012 Mar 27.
Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea - a placebo controlled double-blind randomized, multi-center study.
Arch Med Sci. 2010
Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea - a placebo controlled double-blind randomized, multi-center study.
Sampalis J, Psaradellis E, Rampakakis E. Arch Med Sci. 2010 Mar 1; 6(1):56-64. Epub 2010 Mar 9.
Identification and characterisation of an iron-responsive candidate probiotic.
PLoS One. 2011
Identification and characterisation of an iron-responsive candidate probiotic.
Bailey JR, Probert CS, Cogan TA. PLoS One. 2011; 6(10):e26507. Epub 2011 Oct 19.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.